Together, initial findings suggest a role for APP metabolites as peripheral biomarkers in neurodevelopmental disorders, though further characterization of peripheral APP metabolites and their association with clinical features are needed in FXS. This evidence concerns the gene APP and neurodevelopmental disorder.